Clinical Trial Search

Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants

Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g

Primary: Assessing Percentage of Participants Who Reported Adverse Events Following Treatment by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 — 4.1; 4.3; 4.1; 10…

Primary: Biochemical Failure Free-rate (BFFR) Associated With the Combined Hypofractionated Dose Regimen and Androgen Deprivation Therapy (ADT). — 0 progression events

Primary: Proportion of Participants With Clinically Significant Psychological Distress (Kessler Psychological Distress Scale-10 ≥20) — 9; 14; 57; 48 Participants — p=0.031

Primary: Presence of Carcinoma of the Prostate as Measured by Biopsy — 48; 49 participants — p=0.73

Primary: Number of Participants With Clinically Important Immune-related Adverse Events (for the Lead-In Cohort) — 1; 1; 1; 1 Participants

Primary: Changes From Baseline to After Surgery of Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Infiltrates — 132.2; 153.7; 105.1; 140.5…

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…

Primary: Time to Treatment Failure — 4.5; 6.9 Months

Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale

Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants

Primary: Acute Grade 3 or Higher Treatment-related Toxicity Rate. — 1; 3 participants — p=<0.0001

Primary: Change in Serum Prostate Specific Antigen (PSA) of Prostate Cancer — 0.86 ng/mL — p==0.027

Primary: All Cause Mortality — 171; 183 Participants

Primary: Median Tumor Volume Burden at Baseline Multi-parametric Magnetic Resonance Imaging (mpMRI) Before and After Surgery — 3.44; 0.62 cc

Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151

Primary: Number of Participants With Progression-Free Survival — 66; 84 Participants — p=0.40

Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants

Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)

Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants

Primary: Number of Participants With 5-year Freedom From Prostate Specific Antigen (PSA) Recurrence. — 30 participants

Primary: Number of Participants Who Received At Least 1 Infusion of Sipuleucel-T in Men With Metastatic Castrate-resistant Prostate Cancer (CRPC) — 98 participants

Primary: Apoptotic Index of the Highest Gleason Grade Malignant Epithelium in the Radical Prostatectomy Specimen Obtained After 8-weeks of the Dietary Intervention — 6.9; 5.0…

Primary: Number of Participants With One Grade 1 Adverse Event, More Than One Grade 1 Adverse Event, and One Grade 2 Adverse Event — 4; 2; 4 Participants

Primary: Change in Satisfaction With Care — 0.26; 0.07; 0.28; 0.06 units on a scale

Primary: Uptake and Retention of Eovist in Prostate Cancers — 2.01; 1.857; 2.52; 2.212 contrast enhancement ratio (CER) — p=0.0008

Primary: Time to Progression — 15; 9.6 months

Primary: Risk for Gastrointestinal (GI) and Genitourinary (GU) Toxicity — 0; 0; 0; 1.5 percentage of participants